Bristol-Myers nabs FDA priority review for new Opdivo use in kidney cancer

The FDA put Bristol-Myers Squibb's ($BMY) immuno-oncology drug Opdivo on its priority review fast track for a new use in kidney cancer. It would be yet another new indication for Opdivo, which was first approved for melanoma last year and now boasts two indications in lung cancer. Release